Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123613 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1PDPK1CYP2C9CHRNA7 | |
| SCHEMBL5674345 | 0.79 | PTGS2 (0.83) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL1123595 | 0.77 | KIF11 (0.51) | PTGS2PTGS1PDPK1CYP2C9CA12 | |
| SCHEMBL1123619 | 0.76 | PTGES (0.65) | PTGS2PTGS1PDPK1LMNACYP2C9 | |
| SCHEMBL7216291 | 0.74 | PTGS2 (0.62) | PTGS2PTGS1PDPK1CYP2C9CHRNA7 | |
| SCHEMBL1270876 | 0.74 | PTGS2 (0.62) | PTGS2PTGS1PDPK1CYP2C9CHRNA7 | |
| SCHEMBL1123783 | 0.73 | PTGS2 (0.61) | PTGS2PTGS1PDPK1LMNACYP2C9 | |
| SCHEMBL5594452 | 0.73 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL3246957 | 0.69 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL8121672 | 0.69 | PTGS2 (0.70) | PTGS2PTGS1PDPK1CYP2C9CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | claimed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | claimed |
| EP-2284154-A1 | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | Argon Pharma S.L. (ES) | 2011-02-16 | — | — | EP | claimed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | claimed |
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | disclosed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2284154-A1 | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | Argon Pharma S.L. (ES) | 2011-02-16 | — | — | EP | disclosed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPD52L2, CYC1 | PTGS2 1289/4885PTGS1 1559/4885PDPK1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.